Pedro Esnaola

Pedro Esnaola is an accomplished professional with extensive experience in the biopharmaceutical sector and various leadership roles. As President of Quimatryx since April 2015, Pedro spearheads the discovery and development of novel drugs targeting epigenetic factors in cancer treatment. Additionally, Pedro serves as CPAO at Oncomatryx Biopharma, focusing on precision drugs that disrupt the tumor microenvironment. Formerly a Consul Honorary for Slovenia and holding advisory positions at ZAISA and ORTZIBIA, Pedro's expertise extends across logistics and governing organizations, including leadership roles at the Gipuzkoa Chamber of Commerce and the Basque Health Cluster. Pedro holds a Bachelor's degree in Economics from Universidad del País Vasco and an Executive MBA from the University of Deusto.